A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

NCT02914938 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

97

Enrollment

INDUSTRY

Sponsor class

Stopped discontinuation of zandelisib program

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Follicular Lymphoma (FL)
Marginal Zone B Cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
High Grade Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma (MCL)

Interventions

DRUG: ME-401
DRUG: Rituximab
DRUG: Zanubrutinib

Sponsor

MEI Pharma, Inc.